BACKGROUND: Sacubitril/valsartan (Sac/Val) is superior to angiotensin-converting enzyme
inhibitors in reducing the risk of heart failure hospitalization and cardiovascular death, but its …

Abstract Background: Sacubitril/valsartan (SAC/VAL) is approved by the US Food and Drug
Administration for heart failure with reduced ejection fraction (HFrEF). Objectives: This study …

Background Coronary artery disease is the most common cause of heart failure (HF) in
developed countries. The aim of this study was to elucidate the mechanisms of reduction of …

Background: The current cornerstone treatment of myocardial infarction (MI) is restoration of
coronary blood flow by means of thrombolytic therapy or primary percutaneous coronary …

The effect of ACE inhibition after myocardial infarction (MI) on MI healing and remodeling in
the presence of hypertension is not exactly known. Therefore, the effect of quinapril on scar …

To investigate the role of classical (CLM, CD14++ CD16−), intermediate (INTM, CD14++
CD16+), and non-classical (Non-CLM, CD14+ CD16++) monocytes in scar formation after …

Background: The combination drug sacubitril (neprilysin inhibitor)/valsartan (Ang-II receptor
blocker) is FDA-approved for treatment of HFrEF patients and NYHA class II-IV symptoms …

Background: Sacubitril/Valsartan, a dual inhibitor of the neprilysin and angiotensin receptor,
exerts cardioprotective effects in heart failure. Little is known on the impact of …

Objective The aim of this study was to investigate the effect of sacubitril/valsartan (Sal/Val)
on left ventricular (LV) remodeling in patients with LV systolic dysfunction following acute …

BACKGROUND: We sought to introduce sodium–hydrogen exchange inhibition as
prophylaxis against the development of ventricular dysfunction in the setting of implantable …